A Multi-Country Comparison of COVID-19 Treatment with/without HCQ

[admin]

"Early treatment with hydroxychloroquine: a country-based analysis
Covid Analysis, August 5, 2020 (updated September 6, 2020)"

"Many countries either adopted or declined early treatment with HCQ, effectively forming a large trial with 1.8 billion people in the treatment group and 663 million in the control group. As of September 15, 2020, an average of 65.1 per million in the treatment group have died, and 471.8 per million in the control group, relative risk 0.138. After adjustments, treatment and control deaths become 136.2 per million and 704.7 per million, relative risk 0.19. The probability of an equal or lower relative risk occurring from random group assignments is 0.013. Accounting for predicted changes in spread, we estimate a relative risk of 0.25. The treatment group has a 74.8% lower death rate. Confounding factors affect this estimate. We examined diabetes, obesity, hypertension, life expectancy, population density, urbanization, testing level, and intervention level, which do not account for the effect observed."

https://hcqtrial.com/




https://hcqtrial.com/

Particularly the EARLY OUTpatient studies, most relevant to hydroxychloroquine's performance.

https://c19study.com/#early

Why do poor African countries have less than 1% of the COVID death rate that "developed" western countries do?
https://www.bitchute.com/video/xR4druFBssHd/